L-Base develops cancer-specific autophagy inhibitors targeting the CAGE antigen to overcome resistance in existing cancer therapies. Their peptide-based treatments aim to enhance the efficacy of drugs like Tagrisso in non-small cell lung cancer, improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Existing cancer therapies often face resistance mechanisms, leading to reduced efficacy and poor patient outcomes. Overcoming this resistance is critical for improving treatment success, particularly in cancers like non-small cell lung cancer.
Solution
L-Base is developing cancer-specific autophagy inhibitors that target the CAGE antigen, a protein present in cancer cells but not in normal tissues. By inhibiting autophagy, a cellular process that allows cancer cells to recycle damaged components and survive under stress, L-Base's peptide-based therapeutics aim to overcome resistance to existing cancer treatments. Their lead candidate, LB217, is being developed to enhance the efficacy of drugs like Tagrisso in non-small cell lung cancer. The company utilizes a NanoBRET system to screen and identify novel drug candidates that effectively inhibit the interaction between CAGE and its binding proteins.
Target Audience
The primary target audience includes patients with cancers expressing the CAGE antigen, particularly non-small cell lung cancer, and pharmaceutical companies seeking novel therapeutic approaches to overcome drug resistance.
Features
- CAGE-targeted therapy: Specifically inhibits autophagy in cancer cells expressing the CAGE antigen.
- Peptide-based therapeutics: Utilizes peptides to selectively bind to and inhibit the CAGE protein.
- NanoBRET screening system: Facilitates the discovery of drug candidates that disrupt CAGE protein interactions.
- LB217: Lead drug candidate targeting non-small cell lung cancer, designed for combination therapy with existing drugs like Tagrisso.
- Autophagy inhibition: Blocks the autophagy process in cancer cells, preventing them from recycling cellular components and surviving under stress.